Clinical trial NCT03225066: Efficacy and Safety of Poly-L-lactic Acid
Official title: A Prospective, Randomized, Multicenter, Self-controlled, Blinded Trial on the Efficacy and Safety of Poly-L-lactic Acid - SCULPTRA - for the Treatment of Corporal Skin Flaccidity.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Flaccidity, Muscle
Lead sponsor: Galderma Brasil Ltda.
Sponsor class: INDUSTRY
First posted: 2017-07-21
Enrollment: 70
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The study sample will be stratified to include 50% of subjects, who will receive Sculptra treatment on the antero-medial side of the arms and approximately 50% of subjects, who will receive Sculptra treatment in the gluteal area, in order to exploratory analyzes by subgroup.

During the study, the subjects should come to the research site up to nine times: one for the screening/inclusion visit (SV), three treatment visits (TVs) for Side 1 (from 1 to 14 days after SV, and from 1 to 2 months after first session), three TVs for Side 2 (4, 5 and 6 months after the first S1 treatment session), one follow-up visit (FUV), 6 months after the first S2 treatment session) and a final visit (FV) (12 months after the first S1 session). After 4 months of the first treatment we will compare the results between the first treated side and non-treated side.
Primary purpose: TREATMENT

Brief summary: This study aims to assess efficacy and safety of Sculptra in the treatment of skin flaccidity in selected areas - arms, anteromedial region, and gluteal regions. To assess the efficacy of Sculptra®, via adapted Global Aesthetic Improvement Scale -GAIS- score determined by blind evaluator, in the treatment of skin flaccidity on the anteromedial region of arm and gluteal region, 4 months after initiating the treatment, based on the assessment of the corporal side randomized to be the first to receive treatment . Considering as an alternative hypothesis of interest a 70% value of the subjects the treated side would have higher GAIS than the untreated side.

Detailed description: Ethical and General considerations regarding the study conduction: This study protocol will be reviewed and approved by appropriate IEC/IRB prior to the initiation of the study.

Clinical monitoring: Study conduction will be closely monitored by Galderma representatives, following GCP regulations, applicable standard operating procedures, guides and local regulations.

Data Management: Data may be audited by Galderma Quality Assurance Department and/or CRO prior to or after results of the first statistical analysis on the primary discretion.

Quality assurance, auditing and Inspection: The study will be carried out under the sponsorship of Galderma in accordance with all local and federal regulations, as well as ICH guidelines. Audits and inspections at the research site may be conducted by Galderma representatives or local authorities. All aspects in any study step can be audited by Galderma Quality Assurance / CRO and, as a result, a certificate stating this will be provided.

Eligibility criteria: Inclusion Criteria:

1. Female;
2. Age between 35 and 60 years (including 60 years);
3. Indication for treatment of bilateral skin flaccidity of at least one of two corporal areas candidate for treatment (arms \[anteromedial region\] or gluteal regions);
4. Mild to moderate flaccidity in the area to be treated, according to investigator's assessment and in accordance with appropriated flaccidity scales for corporal region to be treated;
5. Subjects who understood and signed the Informed Consent Form (ICF) when entering the study, before performing any investigational procedure

Exclusion Criteria:

1. Prior use (\<1 year) or planning to use any other aesthetic treatment in the corporal area of interest for study, such as radiofrequency, cryolipolysis;
2. History of liposuction, plastic surgery and / or corrective plastic surgery in the area of the body of interest for the study (arms or gluteal region);
3. History (\<1year) of treatment with Sculptra in other corporal area, area without interest for study;
4. History of Sculptra treatment in the area of the body of interest for the study (arms or gluteal region);
5. Any type of comorbidity or clinical condition that, at investigator s discretion, could interfere with study assessments;
6. Using or planning to initiate restrictive diets (at investigator s discretion);
7. Using or planning to initiate use of supplements for weight loss;
8. Diabetes mellitus type 1 or type 2;
9. Autoimmune diseases, collagenosis, decompensated endocrine diseases or any disease that, at investigator's discretion, could interfere with study assessments;
10. Using or have used within 3 months drugs such as corticosteroids, immunosuppressants or others collagen-production inhibitors;
11. Initiated use of hormones or change in dose of hormonal replacement therapy within 3 months;
12. Practices regularly or intend to practice during the study high-performance or impact physical activities, such as weight lifting, marathon, triathlon;
13. Pregnant or breastfeeding, or wishes to get pregnant within the next 18 months, or refuses to use appropriate contraceptive method (in case of women of childbearing potential).

Primary outcomes:
measure: Assess the aesthetic effect through photographs via GAIS score determined by blind evaluator
timeFrame: 4 months after starting Side 1 treatment
Secondary outcomes:
measure: Assess the frequency with which the blind evaluators identified correctly Side 1, 4 months after initiating treatment on Side 1 through photographs.
timeFrame: 4 months after starting Side 1 treatment
measure: Assess efficacy of Sculptra in the treatment of skin flaccidity via GAIS score determined by the investigator.
timeFrame: 4, 6 and 12 months after starting side 1 treatment and 6 and 8 months after starting side 2
measure: To assess the aesthetic effect of Sculptra in the skin flaccidity treatment, treatment, via GAIS score determined by the research subject.
timeFrame: 4, 6 and 12 months after initiating side 1 as well as 6 and 8 months after initiating side 2 treatment
measure: To assess aesthetic effect of Sculptra on skin flaccidity via GAIS score determined by the investigator
timeFrame: 4 months after initiating side 1 treatment
measure: Evaluate aesthetic effect of Sculptra on skin flaccidity by comparing Side1 to Side2 by the investigator.
timeFrame: 4 months after initiating Side 1 treatment
measure: Assess the aesthetic effect of Sculptra on skin flaccidity, by comparing S1 to S2 by the research subject.
timeFrame: 4 months after initiating side 1 treatment
measure: Assess the effect of Sculptra on dermal thickness, via high-frequency ultrasound.
timeFrame: 4, 6 and 12 months after initiating side 1 treatment as well as 2 and 8 months after initiating Side 2 treatment
measure: Assess the subject s discomfort with Sculptra application.
timeFrame: 1 year
measure: Evaluate Sculptra effect on arm circumference, 4, and 12 months after initiating Side 1 treatment
timeFrame: 4 and 12 months after initiating side 1 treatment
measure: Assess investigator s satisfaction and perception of aesthetic result obtained with Sculptra.
timeFrame: 4, 6 and 12 months after initiating side 1 treatment as well as 6 and 8 months after initiating side 2 treatment
measure: Assess subject s satisfaction and aesthetic result perception obtained with Sculptra
timeFrame: 4, 6 and 12 months after initiating Side 1 treatment, as well as 6 and 8 months after initiating Side2 treatment
measure: Incidence, seriousness, severity and relationship of adverse events with the treatment with Sculptra
timeFrame: An average of 1 year
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Centro Brasileiro de Estudos em Dermatologia
state: RS
city: São Paulo
country: Brazil
facility: Fundação do ABC
state: SP
city: São Paulo
country: Brazil
facility: Hospital Israelita Albert Einstin
state: SP
city: São Paulo
country: Brazil
facility: Universidade Federal de São Paulo - UNIFESP - UNICCO
Study officials:
affiliation: Federal University of São Paulo
name: Samira Yarak
role: PRINCIPAL_INVESTIGATOR
affiliation: Fundacao do ABC
name: Marisa G Cunha
role: PRINCIPAL_INVESTIGATOR
affiliation: Centro Brasileiro de Estudos em Dermatologia
name: Doris M Hexsel
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital Israelita Albert Einstein
name: Alessandra Haddad
role: PRINCIPAL_INVESTIGATOR
References: